Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy  

作　　者：Tarun Sahu Henu Kumar Verma Bhaskar Lvks 

机构地区：[1]Physiology,All India Institute of Medical Science,Raipur 492001,Chhattisgarh,India [2]Department of Immunopathology,Institute of Lung Health and Immunity,Comprehensive Pneumology Center,Helmholtz Zentrum,Munich 80331,Bayren,Germany [3]Zoology,Guru Ghasidas Vishwavidyalaya,Bilaspur 495001,Chhattisgarh,India

出　　处：《World Journal of Virology》2022年第4期204-207,共4页世界病毒学杂志

摘　　要：Patients with lymphoid malignancies are at a higher risk of coronavirus disease 2019(COVID-19)infection due to their immunocompromised state and results in higher mortality rates in these patients.Anti-CD 20 therapy is one of the leading causes of immunosuppression that worsens in COVID-19 cases.COVID-19 vaccines,on the other hand,appear to be less beneficial to these patients.Appropriate treatment and recommendations are required for these COVID-19 patients with lymphoid malignancies.

关 键 词：COVID-19 Lymphoid malignancy LYMPHOMA VACCINATION IMMUNOSUPPRESSION 

分 类 号：R73[医药卫生—肿瘤]